Vol 8, No 2 (2017)
Case report
Published online: 2017-09-06

open access

Page views 1157
Article views/downloads 1498
Get Citation

Connect on Social Media

Connect on Social Media

Successful induction and consolidation chemotherapy in 20-years-old woman with acute promyelocytic leukemia who refused to accept blood transfusion because of religious beliefs

Ilona Szypuła-Perkosz, Ewa Bodzenta, Agnieszka Barchnicka, Elżbieta Chachaj, Janusz Limon, Bożena Jaźwiec, Sebastian Grosicki
Hematologia 2017;8(2):152-158.

Abstract

This paper describes a case of 20 years old woman with acute promyelocytic leukemia who refused to accept blood transfusion because of religious beliefs. Individualized induction chemotherapy with daunorubicin, cladribine, cytarabine and all-trans retinoic acid was administered and complete remission was achieved. Grade 4 leukopenia, anemia and thrombocytopenia was observed during induction chemotherapy. Then three consecutive consolidation cycles were given without important complications. In control molecular analysis after induction-consolidation therapy there was no PML-RARA fusion gene detected.

References

  1. Sanz MA, Montesinos P, Kim HT, et al. IC-APL and PETHEMA and HOVON Groups. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol. 2015; 94(8): 1347–1356.
  2. Sanz MA, Martín G, González M, et al. Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004; 103(4): 1237–1243.
  3. Sanz MA, Montesinos P, Vellenga E. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008; 112(8): 3130–3134.
  4. Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002; 99(3): 759–767.
  5. Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017; 35(6): 605–612.
  6. Burnett AK, Russell NH, Hills RK, et al. UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13): 1295–1305.
  7. Chojnowski K, Janus A, Bliźniewska K, et al. Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah's Witness patient. Transfusion. 2016; 56(10): 2438–2442.
  8. Laszlo D, Agazzi A, Goldhirsch A, et al. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004; 72(4): 264–267.
  9. Brown NM, Keck G, Ford PA. Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma. 2008; 49(4): 817–820.
  10. Cullis JO, Duncombe AS, Dudley JM, et al. Acute leukaemia in Jehovah's Witnesses. Br J Haematol. 1998; 100(4): 664–668.
  11. Mazza P, Palazzo G, Amurri B, et al. Acute leukemia in Jehovah's Witnesses: a challenge for hematologists. Haematologica. 2000; 85(11): 1221–1222.
  12. Keane C, Mollee P, Marlton P, et al. Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Ann Hematol. 2011; 90(3): 359–360.
  13. Lin CP, Huang MJ, Liu HJ, et al. Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. Am J Hematol. 1996; 51(3): 251–252.
  14. Wandt H, Schaefer-Eckart K, Wilhelm M. Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica. 2005; 90(9): 1292–1294.



Hematology in Clinical Practice